Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Reven today announced that the first patient has been dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study ( Identifier: NCT04708340 … Read More

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Reven’s lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients … Read More

Reven’s Co-Founder Michael Volk Appears on Cheddar News

Yesterday co-founder Michael Volk appeared on Cheddar News (40 million pay-tv households) to discuss the future of medicine. In this national broadcasted interview, Mr. Volk shared the company’s goals to bring their flagship platform drug Rejuveinix (RJX) to market. … Read More

Reven Pharmaceuticals Reports A Promising Second Generation Formulation Of Its Lead Anti-sepsis Drug Candidate Rejuveinix (RJX)

Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Biomedicine and Pharmacotherapy.   In this new publication, Reven Pharmaceuticals team reports positive results regarding the safety and preclinical efficacy of a second generation formulation of its lead anti-sepsis drug candidate Rejuveinix (RJX).  … Read More

Reven Holdings Announces First Patient Dosed in RPI015 Clinical Trial Evaluating RJX for High-risk COVID-19

Reven today announced that the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( Identifier:  NCT04708340 … Read More

Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer

Reven has launched its translational oncology program as a new drug discovery and development initiative that is aimed at changing the therapeutic landscape for difficult-to-treat forms of cancer. The overarching goal of this program is to treat cancer patients more effectively by altering the immediate surroundings of their tumor tissue, also known as the tumor microenvironment (TME). … Read More

Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure

New treatment platforms that can prevent acute respiratory distress syndrome (ARDS) or reduce its mortality rate in high-risk coronavirus disease 2019 (COVID-19) patients, such as those with an underlying cancer, are urgently needed. … Read More

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

Reven today announced the provisional acceptance and early online publication of a peer-reviewed article authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and his academic collaborators in the medical journal, Frontiers in Nutrition … Read More

Rationale for a randomized, placebo-controlled, Phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure

New drug products that can effectively improve the ability of supportive care to reduce the risk of ARDS or its mortality rate in COVID-19 patients are urgently needed. Rejuveinix (RJX) is a formulation of physiologically compatible active ingredients, including … Read More

Mitochondrial function and toxicity: Role of the B vitamin family on mitochondrial energy metabolism

The B vitamins are water-soluble vitamins required as coenzymes for enzymes essential for cell function. This review focuses on their essential role in maintaining mitochondrial function and on how mitochondria are compromised by a deficiency of any B vitamin … Read More

Rejuveinix (RJX) as a drug candidate for patients with systemic inflammatory response syndrome (SIRS): Supportive care considerations for COVID-19, cancer, and sepsis

Sepsis is the consequence of a systemic host inflammatory response to an infection with bacteria, fungi or viruses that is further associated with profound metabolic alterations (1-9). Severe sepsis is frequently associated
with septic shock … Read More

Effect of diet composition on acid–base balance in adolescents, young adults and elderly at rest and during exercise

A diet containing plenty of animal proteins and cereal grains and deficient in vegetables and fruits–a typical diet for many Westernized cultures … Read More

The Alkaline Diet: Is There Evidence That an Alkaline pH Diet Benefits Health?

Life on earth depends on appropriate pH levels in and around living organisms and cells. Human life requires a tightly controlled pH level … Read More

RJX Community

RJX Community Reven, never backward, patient forward. — Com·mu·ni·ty (noun): a feeling of fellowship with others. Similar: body, society, collective — Reven has a dedicated mission to serve patients and their loved ones. Amidst these trying times, our collaborations with … Read More